318 related articles for article (PubMed ID: 25971881)
1. Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials.
Valentin N; Acosta A; Camilleri M
Expert Opin Investig Drugs; 2015 Jun; 24(6):769-79. PubMed ID: 25971881
[TBL] [Abstract][Full Text] [Related]
2. Phase II drugs under clinical investigation for the treatment of chronic constipation.
Mozaffari S; Didari T; Nikfar S; Abdollahi M
Expert Opin Investig Drugs; 2014 Nov; 23(11):1485-97. PubMed ID: 24960333
[TBL] [Abstract][Full Text] [Related]
3. Treatment of opioid-induced gut dysfunction.
Holzer P
Expert Opin Investig Drugs; 2007 Feb; 16(2):181-94. PubMed ID: 17243938
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.
Camilleri M
J Clin Invest; 2013 Oct; 123(10):4111-20. PubMed ID: 24084743
[TBL] [Abstract][Full Text] [Related]
5. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.
Manabe N; Wong BS; Camilleri M
Expert Opin Investig Drugs; 2010 Jun; 19(6):765-75. PubMed ID: 20408739
[TBL] [Abstract][Full Text] [Related]
6. Prokinetics in the Management of Functional Gastrointestinal Disorders.
Quigley EMM
Curr Gastroenterol Rep; 2017 Sep; 19(10):53. PubMed ID: 28887755
[TBL] [Abstract][Full Text] [Related]
7. Promotility medications--now and in the future.
Karamanolis G; Tack J
Dig Dis; 2006; 24(3-4):297-307. PubMed ID: 16849857
[TBL] [Abstract][Full Text] [Related]
8. Basic and clinical pharmacology of new motility promoting agents.
Galligan JJ; Vanner S
Neurogastroenterol Motil; 2005 Oct; 17(5):643-53. PubMed ID: 16185302
[TBL] [Abstract][Full Text] [Related]
9. Emerging treatments in Neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist.
Camilleri M; Acosta A
Neurogastroenterol Motil; 2015 Mar; 27(3):324-32. PubMed ID: 25545036
[TBL] [Abstract][Full Text] [Related]
10. Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders.
Peeters TL
Curr Opin Pharmacol; 2006 Dec; 6(6):553-8. PubMed ID: 17011824
[TBL] [Abstract][Full Text] [Related]
11. Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review.
Mosińska P; Salaga M; Fichna J
Expert Opin Investig Drugs; 2016; 25(3):275-86. PubMed ID: 26765585
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders.
Camilleri M; Bueno L; de Ponti F; Fioramonti J; Lydiard RB; Tack J
Gastroenterology; 2006 Apr; 130(5):1421-34. PubMed ID: 16678556
[TBL] [Abstract][Full Text] [Related]
13. Electrical therapies for gastrointestinal motility disorders.
Chen JD; Yin J; Wei W
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):407-418. PubMed ID: 28277856
[TBL] [Abstract][Full Text] [Related]
14. Development of drugs for gastrointestinal motor disorders: translating science to clinical need.
Sanger GJ; Alpers DH
Neurogastroenterol Motil; 2008 Mar; 20(3):177-84. PubMed ID: 18257767
[TBL] [Abstract][Full Text] [Related]
15. Relamorelin for the treatment of gastrointestinal motility disorders.
Chedid V; Camilleri M
Expert Opin Investig Drugs; 2017 Oct; 26(10):1189-1197. PubMed ID: 28847163
[TBL] [Abstract][Full Text] [Related]
16. Drugs acting on serotonin receptors for the treatment of functional GI disorders.
Tonini M; Pace F
Dig Dis; 2006; 24(1-2):59-69. PubMed ID: 16699264
[TBL] [Abstract][Full Text] [Related]
17. Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131.
Van der Ploeg L; Laken H; Sharma S; Datta R; Halem H; Dong J; Touvay C; Teillot M; Noonan P; Tartaglia L; Stoner L; Henderson B; Gottesdiener K; Culler M
Life Sci; 2014 Jul; 109(1):20-9. PubMed ID: 24931905
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacologic treatments of transit disorders].
Manz M; Meier R
Ther Umsch; 2007 Apr; 64(4):227-32. PubMed ID: 17663210
[TBL] [Abstract][Full Text] [Related]
19. Effect of octreotide on gastrointestinal motility in children with functional gastrointestinal symptoms.
Di Lorenzo C; Lucanto C; Flores AF; Idries S; Hyman PE
J Pediatr Gastroenterol Nutr; 1998 Nov; 27(5):508-12. PubMed ID: 9822313
[TBL] [Abstract][Full Text] [Related]
20. Drugs targeting functional bowel disorders: insights from animal studies.
Sanger GJ; Hicks GA
Curr Opin Pharmacol; 2002 Dec; 2(6):678-83. PubMed ID: 12482730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
